Optimization of Frozen Embryo Transfers by Studying Progesterone on the Day of Transfer
OTEC
1 other identifier
observational
115
1 country
1
Brief Summary
The number of embryo transfers after freezing has increased over the last 10 years due to improvements in embryo freezing techniques and in particular the development of vitrification. This has also been made possible by changes in clinical protocols favouring freezing in patients at high risk of hyperstimulation and by different methods of endometrial preparation to receive embryos after rewarming. In fact, embryo transfer requires endometrial preparation to make implantation possible. There are various protocols for endometrial preparation. Endometrial preparations in the natural cycle, with or without induction of ovulation by FSH, require more regular monitoring, and allow the development of a main follicle that will give a corpus luteum that will secrete progesterone in the luteal phase, which can be supported by the supply of exogenous progesterone. In contrast, endometrial preparations in hormone replacement therapy (HRT) cycles are done by administering estradiol orally or transdermally to stimulate endometrial growth while blocking the patient's gonadotropic axis, and administering progesterone in the luteal phase to differentiate the endometrium. This preparation has the advantage of being simpler to monitor and organize. There is currently no consensus on a type of preparation that would give better results, and although the literature seems to show that there would be more miscarriages in a substituted cycle, there does not seem to be any difference in the birth rate per cycle in the end, whatever the type of endometrial preparation. Some teams have shown that in HRT, there appears to be more miscarriage when the progesterone level measured on the day of the frozen embryo transfer is lower, especially below a threshold of 9ng/mL. Labarta showed ESHRE in July 2019 that modifying the endometrial preparation if the progesterone level is below 9ng/mL on the day of transfer by adding subcutaneous progesterone (Progiron) resulted in a lower miscarriage rate, comparable to the usual miscarriage rates in spontaneous pregnancy. Thus, if the miscarriage rate is higher in HRT than in the natural cycle, and if this is related to "luteal insufficiency" characterized by a lower circulating serum progesterone level, the hypothesis of this study in the investigator's population would be that the serum progesterone level on the day of the frozen embryo transfer would be lower in HRT than in the spontaneous cycle.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Mar 2020
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 27, 2020
CompletedStudy Start
First participant enrolled
March 1, 2020
CompletedFirst Posted
Study publicly available on registry
March 2, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2020
CompletedJune 6, 2023
June 1, 2023
10 months
February 27, 2020
June 5, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
The main objective of our study is to compare progesterone levels on the day of embryo transfer according to the endometrial preparation protocol.
Serum progesterone level (ng/ml)
the day of the embryo transfer
Interventions
Serum progesterone level (ng/ml)
Eligibility Criteria
These are MPA patients who have undergone embryo freezing and endometrial preparation for embryo replacement.
You may qualify if:
- Adult patient (≥18 years of age) and under 43 years of age.
You may not qualify if:
- Patients who did not receive progesterone dosing on the day of transfer are excluded from the study.
- Patients who objected to the use of their data.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
CHUNimes
Nîmes, 30029, France
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 27, 2020
First Posted
March 2, 2020
Study Start
March 1, 2020
Primary Completion
December 31, 2020
Study Completion
December 31, 2020
Last Updated
June 6, 2023
Record last verified: 2023-06
Data Sharing
- IPD Sharing
- Will not share